- Análisis
- Análisis Técnico
Pfizer Análisis Técnico - Pfizer Trading: 2022-06-21
Pfizer Resumen de análisis técnico
Por debajo de 46.26
Sell Stop
Por encima de 50.40
Stop Loss
| Indicador | Señal |
| RSI | Comprar |
| MACD | Vender |
| Donchian Channel | Vender |
| MA(200) | Vender |
| Fractals | Vender |
| Parabolic SAR | Vender |
Pfizer Análisis gráfico
Pfizer Análisis técnico
The technical analysis of the Pfizer stock price chart on daily timeframe shows #S-PFE,Daily is retracing under the 200-day moving average MA(200) which has levelled off. RSI is in oversold zone. We believe the bearish momentum will continue after the price breaches below the lower boundary of Donchian channel at 46.26. This level can be used as an entry point for placing a pending order to sell. The stop loss can be placed at 50.40. After placing the order, the stop loss is to be moved every day to the next fractal high, following Parabolic signals. Thus, we are changing the expected profit/loss ratio to the breakeven point. If the price meets the stop loss level (50.40) without reaching the order (46.26), we recommend cancelling the order: the market has undergone internal changes which were not taken into account.
Análisis fundamental de Acciones - Pfizer
Pfizer is buying stake in French vaccine maker Valneva. Will the Pfizer stock price rebound?
Pfizer has agreed to pay €90.5mn for an 8.1% stake in Valneva, in a move that will bolster the French vaccine company’s Lyme disease program. Pfizer is buying the stake at a price of €9.49 a share — a 20% premium to Valneva’s closing price on Friday of €7.94. The proceeds from the transaction disclosed on Monday will go towards developing a Lyme disease joint program. Valneva will fund 40% of the remaining shared development costs, Pfizer will pay Valneva tiered royalties from 14% to 22%, which will be complemented by up to $100 million in payments to Valneva if certain sales milestones are reached. There is currently no vaccine available for Lyme disease, a tick-borne infection that can prove seriously debilitating. Expectations of rising sales are bullish for company’s stock price. However the current setup is bearish for the stock.
- Obtener certificado
Nota:
Este resumen tiene carácter informativo-educativo y se publica de forma gratuita. Todos los datos que contiene este resumen, son obtenidos de fuentes públicas que se consideran más o menos fiables. Además, no hay niguna garantía de que la información sea completa y exacta. En el futuro, los resúmenes no se actualizarán. Toda la información en cada resumen, incluyendo las opiniones, indicadores, gráficos y todo lo demás, se proporciona sólo para la observación y no se considera como un consejo o una recomendación financiera. Todo el texto y cualquier parte suya, así como los gráficos no pueden considerarse como una oferta para realizar alguna transacción con cualquier activo. La compañía IFC Markets y sus empleados en cualquier circunstancia no son responsables de ninguna acción tomada por otra persona durante o después de la observación del resumen.